Endurance Wealth Management’s iShares Biotechnology ETF IBB Stock Holding History

Endurance Wealth Management’s Portfolio IBB Stock Details IBB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-1,600	Closed	-$195K	–	476
2018 Q3	$195K	Hold	1,600	–	–	0.03%	170
2018 Q2	$176K	Sell	1,600 -364	-19%	-$38.9K	0.03%	180
2018 Q1	$210K	Buy	1,964 +164	+9%	+$18.2K	0.04%	174
2017 Q4	$192K	Hold	1,800	–	–	0.03%	171
2017 Q3	$200K	Hold	1,800	–	–	0.03%	172
2017 Q2	$186K	Hold	1,800	–	–	0.03%	173
2017 Q1	$176K	Hold	1,800	–	–	0.03%	177
2016 Q4	$159K	Hold	1,800	–	–	0.03%	184
2016 Q3	$173K	Hold	1,800	–	–	0.03%	178
2016 Q2	$154K	Hold	1,800	–	–	0.03%	180
2016 Q1	$156K	Hold	1,800	–	–	0.02%	178
2015 Q4	$203K	Hold	1,800	–	–	0.04%	160
2015 Q3	$185K	Hold	1,800	–	–	0.03%	171
2015 Q2	$221K	Sell	1,800 -552	-23%	-$66.1K	0.04%	156
2015 Q1	$269K	Hold	2,352	–	–	0.05%	156
2014 Q4	$237K	Buy	+2,352	New	+$229K	0.04%	154

Other funds holding IBB

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return

Natixis Paris, France $24.8B AUM 35.22% 1-Year Est. Return

Endurance Wealth Management's IBB Position: Q4 2018 in Review

Endurance Wealth Management sold out of iShares Biotechnology ETF (IBB) in Q4 2018, closing a stake of 1,600 shares — an estimated $195K sold.

Endurance Wealth Management first reported a position in IBB in Q4 2014 and held it in 16 quarters. The position peaked at $269K in Q1 2015. 649 funds tracked by Wall St. Rank hold IBB as of Q4 2018.

Endurance Wealth Management reported no remaining iShares Biotechnology ETF position as of Q4 2018 after selling out during the quarter.
Endurance Wealth Management sold 1,600 iShares Biotechnology ETF shares in Q4 2018, an estimated $195K.
Endurance Wealth Management first reported a position in iShares Biotechnology ETF in Q4 2014 and held it in 16 quarters.
Endurance Wealth Management's iShares Biotechnology ETF position peaked at $269K in Q1 2015.
649 funds tracked by Wall St. Rank held iShares Biotechnology ETF as of Q4 2018.

Based on Endurance Wealth Management's 13F filing for Q4 2018, filed 14 Jan 2019.